Surgical and systemic management of endometrial cancer

an international survey

Christina Fotopoulou, Robert Kraetschell, Sean Dowdy, Keiichi Fujiwara, Nobuo Yaegashi, Domenica Larusso, Antonio Casado, Sven Mahner, Thomas J. Herzog, Sean Kehoe, Ignace Vergote, David Scott Miller, Christian Marth, Shingo Fujii, Jalid Sehouli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. Methods: After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months. Results: A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 %) and in Asia (67.2 %), as opposed to USA/UK where LND was mainly for staging purposes (53.5 %; p < 0.001). LND was performed up to the renal veins in CE in 86.8 %, in Asia in 80.8 %, in USA/UK in 51.2 % and in SE in 45.1 % (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 %), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 % (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 %; p < 0.001). In total, 94 % of all participants supported the concept of treating EC patients within appropriate clinical trials. Conclusions: There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.

Original languageEnglish (US)
Pages (from-to)897-905
Number of pages9
JournalArchives of Gynecology and Obstetrics
Volume291
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Endometrial Neoplasms
Lymph Node Excision
Northern Asia
Renal Veins
Surveys and Questionnaires
Carboplatin
Therapeutics
Adjuvant Chemotherapy
Paclitaxel
Doxorubicin
Cisplatin
Multicenter Studies
Canada
Germany
Radiotherapy
Clinical Trials
Guidelines
Neoplasms

Keywords

  • Chemotherapy
  • Endometrial cancer
  • Lymph node dissection
  • Survey
  • Toxicity

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Fotopoulou, C., Kraetschell, R., Dowdy, S., Fujiwara, K., Yaegashi, N., Larusso, D., ... Sehouli, J. (2015). Surgical and systemic management of endometrial cancer: an international survey. Archives of Gynecology and Obstetrics, 291(4), 897-905. https://doi.org/10.1007/s00404-014-3510-3

Surgical and systemic management of endometrial cancer : an international survey. / Fotopoulou, Christina; Kraetschell, Robert; Dowdy, Sean; Fujiwara, Keiichi; Yaegashi, Nobuo; Larusso, Domenica; Casado, Antonio; Mahner, Sven; Herzog, Thomas J.; Kehoe, Sean; Vergote, Ignace; Miller, David Scott; Marth, Christian; Fujii, Shingo; Sehouli, Jalid.

In: Archives of Gynecology and Obstetrics, Vol. 291, No. 4, 2015, p. 897-905.

Research output: Contribution to journalArticle

Fotopoulou, C, Kraetschell, R, Dowdy, S, Fujiwara, K, Yaegashi, N, Larusso, D, Casado, A, Mahner, S, Herzog, TJ, Kehoe, S, Vergote, I, Miller, DS, Marth, C, Fujii, S & Sehouli, J 2015, 'Surgical and systemic management of endometrial cancer: an international survey', Archives of Gynecology and Obstetrics, vol. 291, no. 4, pp. 897-905. https://doi.org/10.1007/s00404-014-3510-3
Fotopoulou, Christina ; Kraetschell, Robert ; Dowdy, Sean ; Fujiwara, Keiichi ; Yaegashi, Nobuo ; Larusso, Domenica ; Casado, Antonio ; Mahner, Sven ; Herzog, Thomas J. ; Kehoe, Sean ; Vergote, Ignace ; Miller, David Scott ; Marth, Christian ; Fujii, Shingo ; Sehouli, Jalid. / Surgical and systemic management of endometrial cancer : an international survey. In: Archives of Gynecology and Obstetrics. 2015 ; Vol. 291, No. 4. pp. 897-905.
@article{50ca781b133e48f5b04bbcc04a05a654,
title = "Surgical and systemic management of endometrial cancer: an international survey",
abstract = "Purpose: To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. Methods: After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months. Results: A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 {\%}) and in Asia (67.2 {\%}), as opposed to USA/UK where LND was mainly for staging purposes (53.5 {\%}; p < 0.001). LND was performed up to the renal veins in CE in 86.8 {\%}, in Asia in 80.8 {\%}, in USA/UK in 51.2 {\%} and in SE in 45.1 {\%} (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 {\%}), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 {\%} (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 {\%}; p < 0.001). In total, 94 {\%} of all participants supported the concept of treating EC patients within appropriate clinical trials. Conclusions: There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.",
keywords = "Chemotherapy, Endometrial cancer, Lymph node dissection, Survey, Toxicity",
author = "Christina Fotopoulou and Robert Kraetschell and Sean Dowdy and Keiichi Fujiwara and Nobuo Yaegashi and Domenica Larusso and Antonio Casado and Sven Mahner and Herzog, {Thomas J.} and Sean Kehoe and Ignace Vergote and Miller, {David Scott} and Christian Marth and Shingo Fujii and Jalid Sehouli",
year = "2015",
doi = "10.1007/s00404-014-3510-3",
language = "English (US)",
volume = "291",
pages = "897--905",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Surgical and systemic management of endometrial cancer

T2 - an international survey

AU - Fotopoulou, Christina

AU - Kraetschell, Robert

AU - Dowdy, Sean

AU - Fujiwara, Keiichi

AU - Yaegashi, Nobuo

AU - Larusso, Domenica

AU - Casado, Antonio

AU - Mahner, Sven

AU - Herzog, Thomas J.

AU - Kehoe, Sean

AU - Vergote, Ignace

AU - Miller, David Scott

AU - Marth, Christian

AU - Fujii, Shingo

AU - Sehouli, Jalid

PY - 2015

Y1 - 2015

N2 - Purpose: To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. Methods: After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months. Results: A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 %) and in Asia (67.2 %), as opposed to USA/UK where LND was mainly for staging purposes (53.5 %; p < 0.001). LND was performed up to the renal veins in CE in 86.8 %, in Asia in 80.8 %, in USA/UK in 51.2 % and in SE in 45.1 % (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 %), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 % (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 %; p < 0.001). In total, 94 % of all participants supported the concept of treating EC patients within appropriate clinical trials. Conclusions: There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.

AB - Purpose: To ascertain the spectrum of clinical management of endometrial carcinoma (EC) the largest international survey was conducted to evaluate and identify differences worldwide. Methods: After validation of a 15-item questionnaire regarding surgical and adjuvant treatment of EC in Germany, an English-adapted questionnaire was put online and posted to all the major gynecological cancer Societies worldwide for further distribution commencing in 2010 and continued for 26 months. Results: A total of 618 Institutions around the world participated: Central Europe (CE), Southern Europe (SE), Northern Europe (NE), Asia and USA/Canada/UK. Both a therapeutic and staging value was attributed to systematic pelvic and paraaortic lymph node dissection (LND) in CE (74.6 %) and in Asia (67.2 %), as opposed to USA/UK where LND was mainly for staging purposes (53.5 %; p < 0.001). LND was performed up to the renal veins in CE in 86.8 %, in Asia in 80.8 %, in USA/UK in 51.2 % and in SE in 45.1 % (p < 0.001) of cases. In advanced disease, centers from Asia were treated most with adjuvant chemotherapy alone (93.6 %), as opposed to centers in SE, CE and UK/USA that employed combination chemo-radiotherapy in 90.9 % (p < 0.001) of cases. Paclitaxel/carboplatin was mostly used followed by doxorubicin/cisplatin (75 vs. 23.3 %; p < 0.001). In total, 94 % of all participants supported the concept of treating EC patients within appropriate clinical trials. Conclusions: There is broad range in both the surgical and adjuvant treatment of EC across different countries. Large-scale multicenter prospective trials are warranted to establish consistent, evidence-based guidelines to optimize treatment worldwide.

KW - Chemotherapy

KW - Endometrial cancer

KW - Lymph node dissection

KW - Survey

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84924778403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924778403&partnerID=8YFLogxK

U2 - 10.1007/s00404-014-3510-3

DO - 10.1007/s00404-014-3510-3

M3 - Article

VL - 291

SP - 897

EP - 905

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 4

ER -